1 of 2 Neuren (NEU) – ASX Announcement 21 August 2026 Neuren H1 2026 Financial Results Webinar on 26 August 2026 H1 2026 Financial Results Webinar | Wednesday, 26 August 2026 at 11.00 AM AEST You are invited to register using this link: ...
Neuren H1 2026 Financial Results Webinar on 26 August 2026
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The webinar is scheduled for a specific date and time, and participants can register online. Neuren is focused on developing therapies for serious neurological disorders with limited treatment options. The announcement includes details about Neuren's drug candidates and ongoing clinical trials.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
- DAYBU recommended for approval in the European Union
- Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
- DAYBUE STIX now broadly available in US for Rett syndrome
- Acadia confirms plan to request CHMP re-examination
Later from Neuren Pharmaceuticals
- European Commission grants marketing authorisation for DAYBU
- Half Yearly Report and Accounts
- Growing royalty anchors Neuren first ever dividend program
- Investor presentation, 26 August 2026
- Dividend/Distribution - NEU
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals